iBio platform to be used for anthrax vaccine
The contract, awarded by the U.S. National Institute of Allergy and Infectious Diseases, is worth $1.76 million in its first year, and potentially worth up to $9.9 million depending on the exercise of its options, according to SacBee.com.
The vaccine is to be developed under license with iBio's iBioLaunch vaccine platform. iBioLaunch uses transient gene expression in unmodified green plants to produce vaccines. It has shown successes in the development of novel vaccines for use against both viral and bacterial pathogens.
"The award of this contract to Fraunhofer is an important expression of confidence in the importance of our iBioLaunch and iBioModulator technologies," Terence Ryan, iBio's chief scientific officer, said, SacBee.com reports. "We believe that our portfolio of highly protective anthrax vaccines and monoclonal antibodies, along with this expanded anthrax initiative, will generate significant commercial interest in other novel applications of our technology."
iBio regularly collaborates with corporations and governments to develop therapies and vaccines. The company's technology is currently being used in the development of a influenza vaccine candidates for the U.S. Department of Defense and the Bill & Melinda Gates Foundations.